Vyne Therapeutics Inc (VYNE)

Jan 6, 2025, 7:30 AM EST - 11 days ago

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

Dec 23, 2024, 7:30 AM EST - 25 days ago

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Sep 12, 2024, 8:00 AM EDT - 4 months ago

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

Aug 14, 2024, 8:00 AM EDT - 5 months ago

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 26, 2024, 8:00 AM EDT - 7 months ago

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum

Jun 13, 2024, 9:02 AM EDT - 7 months ago

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

May 9, 2024, 8:00 AM EDT - 9 months ago

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 8:00 AM EDT - 9 months ago

VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor

May 1, 2024, 8:00 AM EDT - 9 months ago

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

Mar 19, 2024, 8:00 AM EDT - 10 months ago

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Feb 29, 2024, 8:00 AM EST - 11 months ago

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 11 months ago

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

Feb 21, 2024, 8:00 AM EST - 11 months ago

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 16, 2024, 6:50 AM EST - 1 year ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI IBIO

Jan 10, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

Jan 3, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

Nov 16, 2023, 4:03 PM EST - 1 year ago

Menlo Ventures Raises $1.35B for AI Investments

Nov 13, 2023, 7:45 AM EST - 1 year ago

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 7, 2023, 8:00 AM EST - 1 year ago

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

Nov 1, 2023, 4:15 PM EDT - 1 year ago

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

Oct 30, 2023, 7:20 AM EDT - 1 year ago

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

Oct 30, 2023, 7:05 AM EDT - 1 year ago

VYNE Therapeutics Announces Private Placement of $88 Million

Oct 30, 2023, 7:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

Sep 6, 2023, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

May 18, 2023, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Attend BIO International Convention

May 11, 2023, 4:01 PM EDT - 1 year ago

VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

Apr 19, 2023, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

Mar 30, 2023, 7:45 AM EDT - 1 year ago

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

Mar 22, 2023, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference

Mar 9, 2023, 4:01 PM EST - 2 years ago

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

Feb 28, 2023, 4:00 PM EST - 2 years ago

VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 22, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

Feb 15, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

Feb 10, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Reverse Stock Split

Jan 9, 2023, 4:01 PM EST - 2 years ago

VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

Dec 12, 2022, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Participate in the LifeSci Partners 12th Annual Corporate Access Event

Dec 7, 2022, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform

Dec 2, 2022, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Participate in Cantor Fitzgerald's Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

Nov 18, 2022, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference

Nov 17, 2022, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo

Nov 10, 2022, 4:01 PM EST - 2 years ago

VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Sep 6, 2022, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 12, 2022, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Reports Second Quarter 2022 Financial Results

Aug 10, 2022, 8:32 AM EDT - 2 years ago

VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

Jul 19, 2022, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference

Jun 17, 2022, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

May 18, 2022, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference

May 12, 2022, 4:05 PM EDT - 2 years ago

VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update